Cargando…
Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
AIM: The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. MATERIALS & METHODS: A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses exam...
Autores principales: | Bhan, Virender, Clift, Fraser, Baharnoori, Moogeh, Thomas, Kimberly, Patel, Barkha P, Blanchette, François, Adlard, Nicholas, Vudumula, Umakanth, Gudala, Kapil, Dutta, Nikkita, Grima, Daniel, Mouallif, Soukaïna, Farhane, Fatine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690431/ https://www.ncbi.nlm.nih.gov/pubmed/37606897 http://dx.doi.org/10.57264/cer-2022-0175 |
Ejemplares similares
-
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022) -
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany
por: Koeditz, Dominik, et al.
Publicado: (2022) -
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
por: Schur, Nadine, et al.
Publicado: (2021) -
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018) -
Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab
por: Craner, Matthew, et al.
Publicado: (2022)